|1.||Bagnato, Anna: 20 articles (12/2014 - 11/2002)|
|2.||Rosanò, Laura: 18 articles (12/2014 - 05/2003)|
|3.||Di Castro, Valeriana: 16 articles (12/2014 - 05/2003)|
|4.||Spinella, Francesca: 16 articles (12/2014 - 05/2003)|
|5.||Natali, Pier Giorgio: 15 articles (12/2014 - 11/2002)|
|6.||Nicotra, Maria Rita: 11 articles (04/2011 - 11/2002)|
|7.||Webb, David J: 8 articles (03/2015 - 08/2002)|
|8.||Dhaun, Neeraj: 6 articles (03/2015 - 07/2009)|
|9.||Cianfrocca, Roberta: 6 articles (12/2014 - 02/2009)|
|10.||Morris, Thomas: 6 articles (05/2013 - 05/2009)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
01/01/1998 - "Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension."
06/01/2014 - "Selective endothelin-A receptor blockade attenuates endotoxin-induced pulmonary hypertension and pulmonary vascular dysfunction."
09/01/2010 - "Aiming at developing new endothelin-A receptor (ETA) antagonist for treatment of pulmonary hypertension, di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe, named GF063, was synthesized at base of selective ETA receptor antagonist BQ485 and selected for the further pharmacological characterization. "
01/01/2006 - "These results indicate that endothelin-A receptor blockade is of potential therapeutic significance in neonates with pulmonary hypertension and abnormal pulmonary arterial remodeling."
09/01/2004 - "We conclude that chronic endothelin A receptor blockade attenuates the progression of pulmonary hypertension and augments alveolar growth in lambs with increased pulmonary blood flow."
03/01/2003 - "Treatment with the endothelin A receptor antagonist significantly reduced the severity of the ischemia/reperfusion injury, as evidenced by lower levels of AST, ALT, and GLDH. "
04/01/2009 - "Acute endothelin-A receptor blockade is superior to chronic blockade in attenuating ischemia/reperfusion injury in failing hearts. "
11/01/2004 - "Our results provide evidence that the new therapeutic approach using an endothelin-A receptor antagonist is effective in reducing hepatic ischemia/reperfusion injury. "
12/01/1997 - "Efficacy of endothelin-1 receptor antagonist for protecting the function of grafted livers from preservation-reperfusion injury in pigs."
11/01/2005 - "The aims of the study were to visualize the dynamics of ischemia-reperfusion injury by real-time myocardial contrast echocardiography and to investigate the cardioprotective effects of the novel endothelin-A receptor antagonist BSF 461314. "
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2015 - "Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis."
11/01/2009 - "Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer."
05/01/2009 - "The endothelin-A receptor (ETAR) has been implicated in the progression of prostate cancer. "
05/01/2008 - "Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells."
08/01/2004 - "Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines."
07/01/2008 - "Improved peripheral perfusion during endothelin--a receptor blockade in patients with type 2 diabetes and critical limb ischemia."
11/01/2004 - "The aim of this study was to investigate a possible protective role of a selective endothelin-A receptor antagonist on hepatic microcirculation after ischemia/reperfusion. "
01/01/2004 - "The objective of this study was to determine whether the simultaneous measurement of tissue pH, pCO(2), and pO(2) with a multiple-parameter fiberoptic sensor (Paratrend 7) can be used for continuous monitoring of hepatic microperfusion in a pig model of hepatic ischemia given endothelin(A) receptor antagonist (ET(A)-RA) or isotonic saline. "
04/01/2009 - "We investigated the effect of chronic versus acute administration of the selective endothelin-A receptor antagonist (ERA) TBC-3214Na during ischemia/reperfusion in failing hearts. "
04/01/2006 - "Among the examined therapeutic strategies aimed at improving the outcome of intestinal microcirculatory dysfunction, endothelin-A receptor antagonist pretreatment and ischemic preconditioning are promising tools to decrease the harmful consequences of ischemia/reperfusion."
|5.||Hypertension (High Blood Pressure)
03/01/1994 - "In this study, we analyzed the expression of endothelin-A receptor gene in the thickened arterial intima of patients with hypertension. "
05/01/2012 - "Chronic endothelin A receptor blockade attenuates contribution of sympathetic nervous system to salt hypertension development in adult but not in young Dahl rats."
11/01/2006 - "Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension."
12/01/2000 - "Endothelin-1 receptor blockade did not affect AngII-induced hypertension but prevented both lesion development and reduction of density of the vascular neural plexus. "
03/01/2000 - "Blockade of endothelin A receptors lowers arterial pressure in animal models of salt-dependent hypertension. "
|6.||Idiopathic pulmonary hypertension
|8.||Endothelin-1 (Endothelin 1)
|2.||Heterologous Transplantation (Xenotransplantation)
|5.||Cardiopulmonary Bypass (Heart-Lung Bypass)